To explore the effects of viral infections on the blood-brain barrier (BBB) and to identify specific therapeutic strategies aimed at protecting BBB function.
Key Findings:
Viral infections can lead to increased BBB permeability through direct neurotropism and immune-mediated damage, which can result in severe neurologic complications.
Current therapeutic options primarily target viral replication, with fewer addressing BBB damage directly, highlighting a gap in treatment strategies.
Biomarkers such as CSF/serum albumin ratio and glial fibrillary acidic protein (GFAP) can indicate BBB integrity, but their specificity may be influenced by confounding factors.
Interpretation:
Understanding the mechanisms of BBB disruption due to viral infections is crucial for developing targeted neuroprotective therapies that can effectively mitigate BBB damage.
Limitations:
Current biomarkers may not specifically reflect BBB damage due to confounding factors such as systemic inflammation or other neurological conditions.
Therapeutic options for directly addressing BBB damage are limited, necessitating further research into innovative treatment approaches.
Conclusion:
Improving knowledge of BBB interactions and damage mechanisms is essential for advancing therapeutic strategies against viral infections, potentially leading to better patient outcomes.
by Sarah A Boardman, Claire Hetherington, Thomas Hughes, Callum Cook, Ian Galea, Orla Hilton, Tom Solomon, Andrew D Luster, Stuart Allan, Evelyn Kurt-Jones, Joe Forth, Adjanie Patabendige, Franklyn N Egbe, Cordelia Dunai, Benedict D Michael
Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.
